Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).
Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients
- Interventions
- Drug: Low molecular weight heparin (LMWH)Drug: other NOACs
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5737
- Registration Number
- NCT05150938
- Locations
- 🇸🇪
Swedish registries, Multiple Locations, Many Locations, Sweden
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
- Conditions
- Coagulation Disorder
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- VarmX B.V.
- Target Recruit Count
- 105
- Registration Number
- NCT05152420
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
- Conditions
- Embolism and Thrombosis
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05128591
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
- Conditions
- ThrombosisMyocardial Infarction
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 30
- Registration Number
- NCT05116995
- Locations
- 🇨🇦
Nova Scotia Health, Halifax, Nova Scotia, Canada
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2601
- Registration Number
- NCT05112666
- Locations
- 🇬🇧
Many locations, Multiple Locations, United Kingdom
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Scotmann Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05088928
- Locations
- 🇵🇰
Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolus
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 89215
- Registration Number
- NCT05083455
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
- Conditions
- Myocardial Infarction, AcuteLeft Ventricular Thrombus
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 560
- Registration Number
- NCT05077683
- Locations
- 🇫🇷
HEGP, Paris, France
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- Conditions
- StrokeIntracranial Arteriosclerosis
- Interventions
- Other: Risk Factor Management
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 1683
- Registration Number
- NCT05047172
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸University of South Alabama University Hospital, Mobile, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05038228
- Locations
- 🇬🇧
Pfizer Investigator, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.